| routes_of_administration = [[Intramuscular injection]]<ref name="Muller1998" /><ref name="Aronson2009">{{cite book|author=Jeffrey K. Aronson|title=Meyler's Side Effects of Endocrine and Metabolic Drugs|url=https://books.google.com/books?id=BWMeSwVwfTkC&pg=PA289|date=21 February 2009|publisher=Elsevier|isbn=978-0-08-093292-7|pages=289–}}</ref><ref name="MortonHall2012" />

 
Gestonorone caproate is a strong, long-acting, and pure [[progestogen]],<ref name="Raspé2013">{{cite book|author=G. Raspé|title=Hormones and Embryonic Development: Advances in The Biosciences|url=https://books.google.com/books?id=Xp3pAgAAQBAJ&pg=PA79|date=22 October 2013|publisher=Elsevier Science|isbn=978-1-4831-5171-7|pages=79}}</ref><ref name="SchooneesDe Klerk1969">{{cite journal|last1=Schoonees|first1=R.|last2=De Klerk|first2=J. N.|last3=Murphy|first3=G. P.|title=The effect of depostat (SH 582) on the baboon prostate|journal=Journal of Surgical Oncology|volume=1|issue=4|year=1969|pages=317–324|issn=0022-4790|doi=10.1002/jso.2930010404}}</ref> possessing no [[androgen]]ic, [[anabolic]], [[antiandrogen]]ic, [[estrogen]]ic, [[antiestrogen]]ic, [[corticosteroid]], or [[teratogen]]ic effects.<ref name="Schering1968">Schering A.G., Berlin (1968). Depostat (SH 582) a new treatment for prostatic hypertrophy.</ref><ref name="AubreyKhosla1971">{{cite journal|last1=Aubrey|first1=D. A.|last2=Khosla|first2=T.|title=The effect of 17-alpha-hydroxy-19-norprogesterone caproate (SH 582) on benign prostatic hypertrophy|journal=British Journal of Surgery|volume=58|issue=9|year=1971|pages=648–652|issn=0007-1323|doi=10.1002/bjs.1800580904}}</ref> In animals, it is approximately 25&nbsp;times more potent than [[progesterone]] or [[hydroxyprogesterone caproate]].<ref name="AubreyKhosla1971" /> In humans, 100 or 200&nbsp;mg intramuscular gestonorone caproate is said to be equivalent to 1000&nbsp;mg intramuscular hydroxyprogesterone caproate.<ref name="pmid5556820">{{cite journal | vauthors = Karlstedt K | title = Progesterone treatment for local recurrence and metastases in carcinoma corporis uteri | journal = Acta Radiologica: Therapy, Physics, Biology | volume = 10 | issue = 2 | pages = 187–92 | year = 1971 | pmid = 5556820 | doi = 10.3109/02841867109129755| url = | quote = The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19-norprogesterone caproate); 100 mg of the latter corresponds to 1000 mg of Proluton Depot.}}</ref><ref name="pmid4261828">{{cite journal | vauthors = Moe N | title = Short-term progestogen treatment of endometrial carcinoma. Histological, histochemical and hormonal studies | journal = Acta Obstet Gynecol Scand | volume = 51 | issue = 1 | pages = 55–62 | year = 1972 | pmid = 4261828 | doi = 10.3109/00016347209154968| url = | quote = Thirteen patients with primary adenocarcinoma of the uterine corpus were treated for 21 days with l7alphahydroxy-progesterone-caproate (Primolut Depot@, Schering), 1000 mg daily, or 17alpha-hydroxy-19-nor-progesterone-caproate (DepostatB, Schering), 200 mg daily. These doses can be considered as equivalent.}}</ref>

 
Like other potent progestins, gestonorone caproate possesses potent [[antigonadotropic]] activity and is capable of markedly suppressing the [[gonad]]al production and circulating levels of sex hormones such as [[testosterone]] and [[estradiol]].<ref name="AubreyKhosla1971" /><ref name="RaspéBrosig2013">{{cite book|author1=G. Raspé|author2=W. Brosig|title=International Symposium on the Treatment of Carcinoma of the Prostate, Berlin, November 13 to 15, 1969: Life Science Monographs|url=https://books.google.com/books?id=8RjLBAAAQBAJ&pg=PA169|date=22 October 2013|publisher=Elsevier|isbn=978-1-4831-8711-2|pages=169}}</ref><ref name="MakrigiannisGaca1971">{{cite journal|last1=Makrigiannis|first1=D.|last2=Gaca|first2=A.|title=Evaluation of Depostat R in prostatic adenoma on the ground of clinical and sphincterotonometric studies|journal=International Urology and Nephrology|volume=3|issue=1|year=1971|pages=21–29|issn=0301-1623|doi=10.1007/BF02081794}}</ref> A clinical study found that 400&nbsp;mg/week intramuscular gestonorone caproate suppressed testosterone levels by 75% in men, while [[orchiectomy]] as a comparator reduced testosterone levels by 91%.<ref name="pmid694436">{{cite journal | vauthors = Sander S, Nissen-Meyer R, Aakvaag A | title = On gestagen treatment of advanced prostatic carcinoma | journal = Scand. J. Urol. Nephrol. | volume = 12 | issue = 2 | pages = 119–21 | year = 1978 | pmid = 694436 | doi = | url = }}</ref><ref name="pmid519881">{{cite journal | vauthors = Kjeld JM, Puah CM, Kaufman B, Loizou S, Vlotides J, Gwee HM, Kahn F, Sood R, Joplin GF | title = Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men | journal = Clinical Endocrinology | volume = 11 | issue = 5 | pages = 497–504 | year = 1979 | pmid = 519881 | doi = 10.1111/j.1365-2265.1979.tb03102.x| url = | quote = Another synthetic gestogen, 17-hydroxy-19-norprogesterone caproate (Depostat-Schering), 400 mg by i.m. weekly injections suppressed T levels to 25% of pretreatment values (Sander er al., 1978).}}</ref> Levels of [[luteinizing hormone]], conversely, remained unchanged.<ref name="pmid694436" /> Gestonorone caproate is administered once weekly by intramuscular injection, via which it acts as a [[depot injection|depot]].<ref name="Denis2012">{{cite book|author=Louis Denis|title=The Medical Management of Prostate Cancer|url=https://books.google.com/books?id=T78hBQAAQBAJ&pg=PT112|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-3-642-73238-6|pages=112â€“|quote=Gestonorone caproate, another progestational agent, was investigated at our institution. Eighteen patients with painful metastatic [prostate cancer] with objective relapse after orchiectomy were treated with 400 mg/week i.m.}}</ref><ref name="RunnebaumRabe2012">{{cite book|author1=Benno Clemens Runnebaum|author2=T. Rabe|author3=L. Kiesel|title=Future Aspects in Contraception: Proceeding of an International Symposium held in Heidelberg, 5â€“8 September 1984 Part 1 Male Contraception|url=https://books.google.com/books?id=GX2oBgAAQBAJ&pg=PA133|date=6 December 2012|publisher=Springer Science & Business Media|isbn=978-94-009-4910-2|pages=133â€“|quote=Gestonorone [caproate] 100 or 200 mg/week i.m.}}</ref><ref name="PalancaJuco2008">{{cite journal|last1=Palanca|first1=Ernesto|last2=Juco|first2=Wilfrido|title=Conservative treatment of benign prostatic hyperplasia|journal=Current Medical Research and Opinion|volume=4|issue=7|year=2008|pages=513â€“520|issn=0300-7995|doi=10.1185/03007997709109342|quote=A study was carried out in 30 male patients with benign prostate hyperplasia to assess the effectiveness of treatment with a progestational agent, gestonorone caproate (200 mg), given intramuscularly every 7 days over a period of 2 to 3 months.}}</ref>
